Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock
(NQ:
XOMAP
)
25.47
UNCHANGED
Streaming Delayed Price
Updated: 1:52 PM EDT, Jun 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,067
Open
25.47
Bid (Size)
25.47 (3,600)
Ask (Size)
25.51 (200)
Prev. Close
25.47
Today's Range
25.47 - 25.49
52wk Range
25.14 - 30.00
Shares Outstanding
N/A
Dividend Yield
8.46%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
June 12, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA ROYALTY CORP (NASDAQ:XOMAP) Passes Navellier’s Little Book Growth Screen with Strong Momentum
↗
May 14, 2026
Via
Chartmill
Performance
YTD
-6.0%
-6.0%
1 Month
+0.3%
+0.3%
3 Month
-1.2%
-1.2%
6 Month
-5.0%
-5.0%
1 Year
-1.7%
-1.7%
More News
Read More
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (NASDAQ:XOMAP) Shines in Growth Screen from Navellier's 'Little Book That Makes You Rich'
↗
April 22, 2026
Via
Chartmill
XOMA Royalty Corp (NASDAQ:XOMAP) Screened as a High-Growth Stock Using Navellier's Strategy
↗
March 31, 2026
Via
Chartmill
XOMA Royalty Declares Quarterly Preferred Stock Dividends
March 18, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
March 18, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
March 12, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Investor Conferences in March
February 18, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
February 09, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces CFO Transition
January 12, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
December 30, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
December 22, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 05, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
November 12, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via
GlobeNewswire
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 22, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
September 17, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
August 20, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
August 13, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
August 11, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 07, 2025
Via
Benzinga
Frequently Asked Questions
Is XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock publicly traded?
Yes, XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is publicly traded.
What exchange does XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock trade on?
XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock?
The ticker symbol for XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is XOMAP on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock?
The current price of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock is 25.47
When was XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock last traded?
The last trade of XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock was at 06/30/26 01:52 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
